Systemic amyloidosis refers to the extracellular deposition of insoluble amyloid fibrils in various organs and tissues. These amyloid fibrils disrupt normal tissue architecture and organ functioning. The diseases associated with systemic amyloidosis include AL amyloidosis, AA amyloidosis and hereditary ATTR amyloidosis. There are various therapeutic products in clinical trials and pipeline for the treatment of systemic amyloidosis. The treatment landscape includes small molecules as well as monoclonal antibodies.


The global Systemic Amyloidosis Therapeutic Market is estimated to be valued at US$ 6.19 billion in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period of 2024-2031.

Key Takeaways
Key players operating in the systemic amyloidosis therapeutic market are AstraZeneca, Attralus, Ionis Pharmaceuticals, Prothena Biosciences, Alexion Pharmaceuticals.
The key opportunities in the market include rising awareness about the diseases, introduction of new treatment options and strong pipeline of drugs. The market players are exploring opportunities in developing regions like Asia Pacific and Latin America through collaborations and licensing agreements.

Market drivers and restrain
The key drivers for the growth of systemic amyloidosis therapeutic market include increasing drug approvals and launches. For instance, in 2019, the FDA approved tafamidis (Vyndaqel and Vyndamax) developed by Pfizer for the treatment of ATTR amyloidosis. The drug witnessed high adoption rate owing to its effectiveness.
However, lack of understanding about rare nature of diseases like amyloidosis remains a major challenge. Also, high cost of therapies poses difficulty for healthcare systems of developing nations to provide access to treatment.


Segment Analysis
The systemic amyloidosis therapeutic market covers different types of amyloidosis such as light-chain (AL) amyloidosis, hereditary amyloidosis, and wild-type transthyretin amyloidosis. Light-chain (AL) amyloidosis accounts for majority of the cases and holds the largest share in the market currently. It is caused due to abnormal production of light chains of antibodies or immunoglobulins by plasma cells. Wild-type transthyretin amyloidosis is also a dominating sub segment due to increasing levels of wild-type ATTR amyloidosis cases being identified.

Global Analysis
Geographically, North America is expected to dominate the market during the forecast period. Increasing awareness about amyloidosis and presence of key market players are factors driving the market in the region. The Asia Pacific region is projected to be the fastest growing regional market by 2031 due to rising prevalence of light-chain amyloidosis, increasing healthcare expenditure, and expanding healthcare infrastructure.

Get more insights on this topic : https://justpaste.it/702t2

What Are The Key Data Covered In This Systemic Amyloidosis Therapeutic  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Systemic Amyloidosis Therapeutic 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Systemic Amyloidosis Therapeutic  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Systemic Amyloidosis Therapeutic  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Systemic Amyloidosis Therapeutic  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it